Heron Therapeutics Dirección
Dirección controles de criterios 1/4
El CEO de Heron Therapeutics' es Craig Collard, nombrado en Apr 2023, tiene una permanencia de 1.17 años. posee directamente un 0.16% de las acciones de la empresa, con un valor de $763.52K. La antigüedad media del equipo directivo y de la junta directiva es de 1.1 años y 2.8 años, respectivamente.
Información clave
Craig Collard
Chief Executive Officer (CEO)
US$5.5k
Compensación total
| Porcentaje del salario del CEO | n/a |
| Permanencia del CEO | 1.3yrs |
| Participación del CEO | 0.2% |
| Permanencia media de la dirección | 1.2yrs |
| Promedio de permanencia en la Junta Directiva | 2.8yrs |
Actualizaciones recientes de la dirección
Recent updates
Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Share Price Boosted 31% But Its Business Prospects Need A Lift Too
May 30
Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain
Apr 16Here's What Analysts Are Forecasting For Heron Therapeutics, Inc. (NASDAQ:HRTX) After Its Full-Year Results
Mar 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Surges 27% Yet Its Low P/S Is No Reason For Excitement
Feb 15Heron Therapeutics, Inc. (NASDAQ:HRTX) Held Back By Insufficient Growth Even After Shares Climb 27%
Dec 22Heron wins FDA nod for post-operative agent to address nausea and vomiting
Sep 16Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
Aug 10Heron Therapeutics Q2 2022 Earnings Preview
Aug 08Heron Therapeutics proposes 34% cut in workforce as part of cost reduction plan
Jun 30Heron Therapeutics: Cash Is A Problem Again
Mar 31Heron Therapeutics: Changing Strategy After Disappointing Earnings
Mar 03Health Check: How Prudently Does Heron Therapeutics (NASDAQ:HRTX) Use Debt?
Jan 19Heron Therapeutics: Looking For Signs Of The Bottom
Oct 07Is Heron Therapeutics (NASDAQ:HRTX) Using Too Much Debt?
Oct 03Need To Know: Analysts Just Made A Substantial Cut To Their Heron Therapeutics, Inc. (NASDAQ:HRTX) Estimates
Aug 11Shareholders May Be A Bit More Conservative With Heron Therapeutics, Inc.'s (NASDAQ:HRTX) CEO Compensation For Now
Jun 11Heron Therapeutics files for 12.4M common stock offering from shareholder
May 28Is Heron Therapeutics (NASDAQ:HRTX) A Risky Investment?
May 19Heron Therapeutics EPS misses by $0.03, misses on revenue
May 10Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Shift From Loss To Profit
Mar 10CEO
Craig Collard (58 yo)
1.3yrs
Permanencia
US$5,486
Compensación
Mr. Craig Alexander Collard serves as Chief Executive Officer at Heron Therapeutics, Inc. since April 3, 2023 and its Director since February 2023. He had been Chief Executive Officer of Veloxis Pharmaceut...
Equipo directivo
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.3yrs | US$5.49k | 0.16% $ 821.5k | |
| Executive VP & CFO | 1.1yrs | US$1.76m | 0.067% $ 347.8k | |
| Executive VP & Chief Development Officer | 1.1yrs | US$1.71m | 0.063% $ 331.0k | |
| Vice President of Marketing | less than a year | sin datos | sin datos | |
| Senior Vice President of Human Resources | 8.8yrs | sin datos | sin datos | |
| Senior Vice President of Oncology Care Franchise & Commercial Operations | 1.5yrs | sin datos | sin datos | |
| Executive Director | no data | sin datos | sin datos |
1.2yrs
Permanencia media
55yo
Promedio de edad
Equipo directivo experimentado: El equipo directivo de HRTX no se considera experimentado ( 1.1 años antigüedad media), lo que sugiere un nuevo equipo.
Miembros de la Junta
| Nombre | Posición | Permanencia | Compensación | Propiedad |
|---|---|---|---|---|
| CEO & Director | 1.4yrs | US$5.49k | 0.16% $ 821.5k | |
| Independent Director | 10.5yrs | US$11.02m | 0.034% $ 180.0k | |
| Independent Director | 8.1yrs | US$70.51k | 0.035% $ 181.2k | |
| Independent Director | 2.8yrs | US$65.63k | 0.035% $ 183.7k | |
| Independent Chairman | 1.4yrs | US$545.53k | 0.0063% $ 32.9k | |
| Independent Director | 2.8yrs | US$55.00k | 0.035% $ 183.7k |
2.8yrs
Permanencia media
57.5yo
Promedio de edad
Junta con experiencia: La junta directiva de HRTX no se considera experimentada (2.8 años de permanencia promedio), lo que sugiere una nueva junta directiva.